By transplanting the variable domains of this anti-TIGIT mAb onto various antibody backbones, we show that a functionally intact Fc backbone is required for the antitumor activity of the anti-TIGIT mAb across several syngeneic murine tumor models. This evidence concerns the gene TIGIT and neoplasm.